Business
AGM Statement
AGM Statement.
About this update from Talisman Metals Plc
[{"type":"text","content":"\n \nRNS Number : 3241I Ovoca Bio PLC 08 August 2019 \n\n8 August 2019\n \nOvoca Bio plc\n(\"Ovoca\" or the \"Company\")\n \nAGM Statement\n \n \nOvoca Bio plc (LSE: OVB; ISE: OVXA) will hold its Annual General Meeting (\"AGM\") at 12.00 p.m. today at Buswells Hotel, 23-25 Molesworth Steet, Dublin, Ireland. At the AGM, Kirill Golovanov, Chief Executive of Ovoca, will make the following statement:\n\"At today's AGM, it is an opportunity to reflect on a year of great operational progress for Ovoca and to reaffirm some of our expected milestones. Key to the company's future strategic direction has been the acquisition of IVIX LLC, with its investigational drug, Libicore (BP-101), for female sexual dysfunction. In March of this year, we executed on the final part of the transaction disclosed at the time of the initial investment, namely the purchase of a further 9.9% of IVIX to bring our shareholding to 59.9%. Simultaneously, we announced the top line results of IVIX's Phase 3 trial of Libicore in Russia, showing achievement of primary and key secondary endpoints without concern for the safety profile. IVIX had enrolled this study comfortably ahead of schedule, and the study was successfully completed early. \nWith the positive outcome of the Phase 3 study, this has allowed the focus to shift to completing the filing package for marketing authorization in the first launch market, namely the Russian Federation. As indicated in previous statements, Ovoca currently intends to file with the Russian Ministry of Health later this quarter. The usual length of time before an approval decision is issued by the Ministry is approximately 12 months after the date of application filing. During the intervening period, Ovoca will be implementing its plans for Libicore in the rest of the world, supporting further pre-clinical and clinical studies necessary before filing for marketing authorisation in the West.\" \n \n \nENDS\n \n \nFor further information: \nOvoca Bio plc \nKirill Golovanov (Chief Executive)\nTel +353 1 661 9819\[email protected]\n \nDavy (Nominated Adviser, Euronext Growth Advisor and Broker)\nJohn Frain / Daragh O'Reilly\nTel: +353 1 679 6363\n \n \nAbout IVIX: \nIVIX, a Russian‐incorporated company, was formed in 2012 and since that time has sought to ...